SCHEMBL20565611

SCHEMBL20565611

O=C(O)C1CCN(c2ncc(F)c(Cl)n2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.54
CYP2C19 P33261 1/20 0.54
HPGD P15428 2/20 0.50
HSD17B10 Q99714 2/20 0.50
USP2 O75604 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
NEK2 P51955 2/20 0.43
ALDH1A1 P00352 2/20 0.43
NOTUM Q6P988 6/20 0.42
CHRM4 P08173 1/20 0.41
IDH2 P48735 1/20 0.41
MALT1 Q9UDY8 1/20 0.40
TMPRSS15 P98073 1/20 0.40
SCN9A Q15858 1/20 0.40
MAPT P10636 2/20 0.39
APAF1 O14727 1/20 0.39
NSD2 O96028 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20565681 0.86 KDM4E (0.56) KDM4ECYP2C19HPGDHSD17B10USP2
Hydrochloric Acid SCHEMBL20565233 0.84 KDM4E (0.55) KDM4ECYP2C19HPGDHSD17B10USP2
SCHEMBL20564608 0.81 KDM4E (0.51) KDM4ECYP2C19HPGDHSD17B10USP2
SCHEMBL25294566 0.81 KDM4E (0.51) KDM4ECYP2C19HPGDHSD17B10USP2
SCHEMBL30338757 0.81 KDM4E (0.51) KDM4ECYP2C19HPGDHSD17B10USP2
SCHEMBL25302383 0.80 KDM4E (0.50) KDM4ECYP2C19HPGDHSD17B10USP2
SCHEMBL30547523 0.80 KDM4E (0.50) KDM4ECYP2C19HPGDHSD17B10USP2
SCHEMBL25254837 0.80 KDM4E (0.50) KDM4ECYP2C19HPGDHSD17B10USP2
SCHEMBL30547488 0.80 KDM4E (0.50) KDM4ECYP2C19HPGDHSD17B10USP2
SCHEMBL12716919 0.79 KDM4E (0.68) KDM4ECYP2C19HPGDHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011338-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2025-01-09 US disclosed
US-12129263-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2024-10-29 US disclosed
US-20220041620-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2022-02-10 US disclosed
US-11203600-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2021-12-21 US disclosed
EP-3624797-A1 KINASE INHIBITORS AND USES THEREOF Denali Therapeutics Inc. (US) 2020-03-25 EP disclosed
US-20200087319-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2020-03-19 US disclosed
WO-2018213632-A1 KINASE INHIBITORS AND USES THEREOF DENALI THERAPEUTICS INC. (US) 2018-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011338-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 KDM4E 1312/4885CYP2C19 4172/4885HPGD 2930/4885
US-20200087319-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 KDM4E 1312/4885CYP2C19 4172/4885HPGD 2930/4885
US-11203600-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 KDM4E 1312/4885CYP2C19 4172/4885HPGD 2930/4885
US-20220041620-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 KDM4E 1312/4885CYP2C19 4172/4885HPGD 2930/4885
US-12129263-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 KDM4E 1312/4885CYP2C19 4172/4885HPGD 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.